PD LRRK2 Kinase Inhibitor Companies

LRRK2 Kinase Inhibitor Companies for Parkinson's Disease

<div class="infobox">
<div class="infobox-header">LRRK2 Inhibitor Pipeline Overview</div>
<div class="infobox-content">
<table>
<tr><th>Total Companies</th><td>9</td></tr>
<tr><th>Phase 2</th><td>3</td></tr>
<tr><th>Phase 1</th><td>2</td></tr>
<tr><th>Preclinical</th><td>2</td></tr>
<tr><th>Discovery</th><td>2</td></tr>
</table>
</div>
</div>

Overview

Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of familial Parkinson's disease, accounting for approximately 5-10% of cases. The G2019S mutation alone accounts for roughly 5% of all PD cases. LRRK2 kinase inhibitors represent one of the most advanced disease-modifying therapeutic approaches for genetically-defined PD.

For detailed mechanism information, see [LRRK2 Kinase Pathway in Parkinson's Disease](/mechanisms/lrrk2-kinase-pathway-parkinsons) and [LRRK2 Inhibitors for Parkinson's Disease](/therapeutics/lrrk2-inhibitors-parkinsons).

Clinical-Stage Programs

Phase 2

| Company | Drug | Mechanism | Status | Development Notes |
|---------|------|-----------|--------|-------------------|
| Biogen/Denali | BIIB122 (DNL151) | LRRK2 inhibitor | Phase 2b (LUMA trial) | Partnership; globally enrolled |
| Neuron23 | NEU-411 | LRRK2 inhibitor | Phase 2 (NEULARK trial) | Precision medicine approach; LRRK2+ patients only |
| Vanqua Bio/Genentech | G007-LK (VQVN-0001) | LRRK2 inhibitor | Phase 1/2 | Collaboration with Genentech/Roche |

Phase 1

LRRK2 Kinase Inhibitor Companies for Parkinson's Disease

<div class="infobox">
<div class="infobox-header">LRRK2 Inhibitor Pipeline Overview</div>
<div class="infobox-content">
<table>
<tr><th>Total Companies</th><td>9</td></tr>
<tr><th>Phase 2</th><td>3</td></tr>
<tr><th>Phase 1</th><td>2</td></tr>
<tr><th>Preclinical</th><td>2</td></tr>
<tr><th>Discovery</th><td>2</td></tr>
</table>
</div>
</div>

Overview

Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of familial Parkinson's disease, accounting for approximately 5-10% of cases. The G2019S mutation alone accounts for roughly 5% of all PD cases. LRRK2 kinase inhibitors represent one of the most advanced disease-modifying therapeutic approaches for genetically-defined PD.

For detailed mechanism information, see [LRRK2 Kinase Pathway in Parkinson's Disease](/mechanisms/lrrk2-kinase-pathway-parkinsons) and [LRRK2 Inhibitors for Parkinson's Disease](/therapeutics/lrrk2-inhibitors-parkinsons).

Clinical-Stage Programs

Phase 2

| Company | Drug | Mechanism | Status | Development Notes |
|---------|------|-----------|--------|-------------------|
| Biogen/Denali | BIIB122 (DNL151) | LRRK2 inhibitor | Phase 2b (LUMA trial) | Partnership; globally enrolled |
| Neuron23 | NEU-411 | LRRK2 inhibitor | Phase 2 (NEULARK trial) | Precision medicine approach; LRRK2+ patients only |
| Vanqua Bio/Genentech | G007-LK (VQVN-0001) | LRRK2 inhibitor | Phase 1/2 | Collaboration with Genentech/Roche |

Phase 1

| Company | Drug | Mechanism | Status |
|---------|------|-----------|--------|
| Novartis | UNR161 | LRRK2 inhibitor | Phase 1 |
| Denali | DNL343 | LRRK2 inhibitor | Phase 1 |

Preclinical & Discovery Programs

| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Bristol-Myers Squibb | BMS-986260 | LRRK2 inhibitor | Discovery |
| GSK | GSK-123 | LRRK2 inhibitor | Preclinical |
| Biogen/Ionis | BIIB132 | LRRK2 ASO | Phase 1 |
| Merck | Undisclosed program | LRRK2 inhibitor | Discovery |

Company Profiles

Biogen

• Mechanism: ATP-competitive LRRK2 kinase inhibitor
• Status: Phase 2b LUMA trial enrolling
• Target engagement: Demonstrated dose-dependent pSer935-LRRK2 reduction
• Page: [Biogen](/companies/biogen)

Denali Therapeutics

• Mechanism: LRRK2 kinase inhibition
• Status: BIIB122 in Phase 2b; DNL343 in Phase 1
• Partnerships: Biogen (BIIB122), Biogen/Ionis (BIIB132 ASO)
• Page: [Denali Therapeutics](/companies/denali-therapeutics)

Neuron23

• Mechanism: Brain-penetrant LRRK2 kinase inhibitor
• Status: Phase 2 (NEULARK trial, NCT06436589)
• Differentiator: Precision medicine — exclusively enrolling LRRK2 mutation carriers
• Funding: $96.5M Series D (2025)
• Page: [Neuron23](/companies/neuron23)

Vanqua Bio

• Mechanism: Potent, selective, brain-penetrant LRRK2 inhibitor
• Status: Phase 1/2 with Genentech/Roche collaboration
• Differentiator: Next-generation chemistry; validated biomarker (pSer935-LRRK2)
• Page: [Vanqua Bio](/companies/vanqua-bio)

Genentech/Roche

• Mechanism: LRRK2 kinase inhibition
• Status: Collaborative development with Vanqua Bio
• Page: [Genentech](/companies/genentech), [Roche](/companies/roche)

Novartis

• Mechanism: ATP-competitive LRRK2 inhibitor
• Status: Phase 1
• Page: [Novartis](/companies/novartis)

Bristol-Myers Squibb

• Mechanism: LRRK2 inhibitor
• Status: Discovery
• Page: [Bristol-Myers Squibb](/companies/bristol-myers-squibb)

GSK

• Mechanism: LRRK2 inhibitor
• Status: Preclinical
• Page: [GSK](/companies/gsk)

Merck

• Mechanism: LRRK2 inhibitor
• Status: Discovery
• Page: [Merck](/companies/merck)

Competitive Landscape

The LRRK2 inhibitor field has evolved significantly since the first-generation inhibitors. Key differentiators include:

Pipeline Summary

Cross-References

• [LRRK2 Kinase Pathway](/mechanisms/lrrk2-kinase-pathway-parkinsons)
• [LRRK2 Inhibitors for PD](/therapeutics/lrrk2-inhibitors-parkinsons)
• [PD Pipeline](/companies/pd-pipeline)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [LRRK2 Gene](/genes/lrrk2)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving PD LRRK2 Kinase Inhibitor Companies discovered through SciDEX knowledge graph analysis: